Skip to main content
NCBI home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
letter
. 1997 Jan;60(1):233–237.

Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine.

I Schuffenecker, N Ginet, D Goldgar, C Eng, B Chambe, A Boneu, C Houdent, D Pallo, M Schlumberger, C Thivolet, G M Lenoir
PMCID: PMC1712555  PMID: 8981969

Full text

PDF
233

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bolino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T., Chabrier G., Houdent C., Murat A., Schlumberger M. RET mutations in exons 13 and 14 of FMTC patients. Oncogene. 1995 Jun 15;10(12):2415–2419. [PubMed] [Google Scholar]
  2. Carlson K. M., Bracamontes J., Jackson C. E., Clark R., Lacroix A., Wells S. A., Jr, Goodfellow P. J. Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet. 1994 Dec;55(6):1076–1082. [PMC free article] [PubMed] [Google Scholar]
  3. Carlson K. M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C. E., Wells S. A., Jr, Goodfellow P. J., Donis-Keller H. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1579–1583. doi: 10.1073/pnas.91.4.1579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eng C., Mulligan L. M., Smith D. P., Healey C. S., Frilling A., Raue F., Neumann H. P., Ponder M. A., Ponder B. A. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995 Jul;43(1):123–127. doi: 10.1111/j.1365-2265.1995.tb01903.x. [DOI] [PubMed] [Google Scholar]
  5. Eng C., Smith D. P., Mulligan L. M., Healey C. S., Zvelebil M. J., Stonehouse T. J., Ponder M. A., Jackson C. E., Waterfield M. D., Ponder B. A. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene. 1995 Feb 2;10(3):509–513. [PubMed] [Google Scholar]
  6. Eng C., Smith D. P., Mulligan L. M., Nagai M. A., Healey C. S., Ponder M. A., Gardner E., Scheumann G. F., Jackson C. E., Tunnacliffe A. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 1994 Feb;3(2):237–241. doi: 10.1093/hmg/3.2.237. [DOI] [PubMed] [Google Scholar]
  7. Hofstra R. M., Landsvater R. M., Ceccherini I., Stulp R. P., Stelwagen T., Luo Y., Pasini B., Höppener J. W., van Amstel H. K., Romeo G. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994 Jan 27;367(6461):375–376. doi: 10.1038/367375a0. [DOI] [PubMed] [Google Scholar]
  8. Jing S., Wen D., Yu Y., Holst P. L., Luo Y., Fang M., Tamir R., Antonio L., Hu Z., Cupples R. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell. 1996 Jun 28;85(7):1113–1124. doi: 10.1016/s0092-8674(00)81311-2. [DOI] [PubMed] [Google Scholar]
  9. Kitamura Y., Scavarda N., Wells S. A., Jr, Jackson C. E., Goodfellow P. J. Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B. Hum Mol Genet. 1995 Oct;4(10):1987–1988. doi: 10.1093/hmg/4.10.1987. [DOI] [PubMed] [Google Scholar]
  10. Lairmore T. C., Dou S., Howe J. R., Chi D., Carlson K., Veile R., Mishra S. K., Wells S. A., Jr, Donis-Keller H. A 1.5-megabase yeast artificial chromosome contig from human chromosome 10q11.2 connecting three genetic loci (RET, D10S94, and D10S102) closely linked to the MEN2A locus. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):492–496. doi: 10.1073/pnas.90.2.492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Love D. R., Gardner E., Ponder B. A. A polymorphic dinucleotide repeat at the ZNF22 locus. Hum Mol Genet. 1993 Apr;2(4):491–491. [PubMed] [Google Scholar]
  12. Modigliani E., Vasen H. M., Raue K., Dralle H., Frilling A., Gheri R. G., Brandi M. L., Limbert E., Niederle B., Forgas L. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. J Intern Med. 1995 Oct;238(4):363–367. doi: 10.1111/j.1365-2796.1995.tb01211.x. [DOI] [PubMed] [Google Scholar]
  13. Mulligan L. M., Eng C., Healey C. S., Clayton D., Kwok J. B., Gardner E., Ponder M. A., Frilling A., Jackson C. E., Lehnert H. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet. 1994 Jan;6(1):70–74. doi: 10.1038/ng0194-70. [DOI] [PubMed] [Google Scholar]
  14. Mulligan L. M., Eng C., Healey C. S., Ponder M. A., Feldman G. L., Li P., Jackson C. E., Ponder B. A. A de novo mutation of the RET proto-oncogene in a patient with MEN 2A. Hum Mol Genet. 1994 Jun;3(6):1007–1008. doi: 10.1093/hmg/3.6.1007. [DOI] [PubMed] [Google Scholar]
  15. Mulligan L. M., Kwok J. B., Healey C. S., Elsdon M. J., Eng C., Gardner E., Love D. R., Mole S. E., Moore J. K., Papi L. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993 Jun 3;363(6428):458–460. doi: 10.1038/363458a0. [DOI] [PubMed] [Google Scholar]
  16. Nakamura Y., Gillilan S., O'Connell P., Leppert M., Lathrop G. M., Lalouel J. M., White R. Isolation and mapping of a polymorphic DNA sequence pYNH24 on chromosome 2 (D2S44). Nucleic Acids Res. 1987 Dec 10;15(23):10073–10073. doi: 10.1093/nar/15.23.10073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pasini B., Hofstra R. M., Yin L., Bocciardi R., Santamaria G., Grootscholten P. M., Ceccherini I., Patrone G., Priolo M., Buys C. H. The physical map of the human RET proto-oncogene. Oncogene. 1995 Nov 2;11(9):1737–1743. [PubMed] [Google Scholar]
  18. Ponder B. A. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2. Cancer Surv. 1995;25:195–205. [PubMed] [Google Scholar]
  19. Rossel M., Schuffenecker I., Schlumberger M., Bonnardel C., Modigliani E., Gardet P., Navarro J., Luo Y., Romeo G., Lenoir G. Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families. Hum Genet. 1995 Apr;95(4):403–406. doi: 10.1007/BF00208964. [DOI] [PubMed] [Google Scholar]
  20. Sapienza C. Parental origin effects, genome imprinting, and sex-ratio distortion: double or nothing? Am J Hum Genet. 1994 Dec;55(6):1073–1075. [PMC free article] [PubMed] [Google Scholar]
  21. Schuffenecker I., Billaud M., Calender A., Chambe B., Ginet N., Calmettes C., Modigliani E., Lenoir G. M. RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet. 1994 Nov;3(11):1939–1943. doi: 10.1093/hmg/3.11.1939. [DOI] [PubMed] [Google Scholar]
  22. Trupp M., Arenas E., Fainzilber M., Nilsson A. S., Sieber B. A., Grigoriou M., Kilkenny C., Salazar-Grueso E., Pachnis V., Arumäe U. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature. 1996 Jun 27;381(6585):785–789. doi: 10.1038/381785a0. [DOI] [PubMed] [Google Scholar]
  23. Wohllk N., Cote G. J., Bugalho M. M., Ordonez N., Evans D. B., Goepfert H., Khorana S., Schultz P., Richards C. S., Gagel R. F. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 1996 Oct;81(10):3740–3745. doi: 10.1210/jcem.81.10.8855832. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES